Investor Contact: Jeffrey Geyer, [email protected] , 305-317-3012
Media Contact: Caroline Zubieta, [email protected] , 562-542-1845 Molina Healthcare Reports Third Quarter 2026 Financial Results
– Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Financial results are summarized below:
• As of September 30, 2026, the Company served approximately 4.9 million members.
• Premium revenue was approximately $10.5 billion for the third quarter of 2026.
• Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income per diluted share was $0.89.
• The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.
“We are pleased with our third quarter results in this challenging environment and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief Executive Officer. “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.” -MORE- Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Premium revenue was approximately $10.5 billion for the third quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower membership in Medicaid and Marketplace, partially offset by rate updates.
GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share, a decrease of 52% year over year. Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of 53% year over year. The decrease is attributed mainly to a higher consolidated MCR.
• The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting rate updates and stable medical cost trend.
• The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting stable medical cost trend.
• The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with normal seasonality and the Company’s expectations.
The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4% and 6.3%, respectively, reflecting continued operating discipline.
Cash and investments at the parent company were approximately $608 million as of September 30, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at September 30, 2026, was 44, consistent with June 30, 2026.
Operating cash flow for the nine months ended September 30, 2026, was $629 million, compared to an outflow of $237 million for the nine months ended September 30, 2025. The increase compared to the prior year was driven mainly by lower government receivable and payable settlements in 2026.
Premium revenue guidance for the full year is unchanged at approximately $42 billion.
The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share. Guidance metrics across all segments are also reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027. -MORE- Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, October 22, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6534841. A telephonic replay of the conference call will be available through Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation number 4361465 . A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com . A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Reports on Form 10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov . Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 21, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations. -MORE- Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
September 30, 2026 Unaudited (Dollars in millions, ASSETS except per-share December 31, Current assets: amounts) 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 4,479 $ 4,248 equivalents Investments 4,100 4,008 Receivables 3,359 3,533 Prepaid expenses and other current 576 655 assets Total current assets 12,514 12,444 Property, equipment, and capitalized 324 301 software, net Goodwill and intangible assets, 2,073 2,195 net Restricted 345 299 investments Deferred income 267 178 taxes, net Other assets 129 147 Total assets $ 15,652 $ 15,564 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Medical claims and $ 4,988 $ 4,887 benefits payable Amounts due 1,141 1,326 government agencies Accounts payable, accrued liabilities 1,183 1,093 and other Deferred revenue 82 66 Total current 7,394 7,372 liabilities Long-term debt 3,771 3,766 Finance lease 179 184 liabilities Other long-term 153 173 liabilities Total liabilities 11,497 11,495 Stockholders’ equity: Common stock, $0.001 par value, 150 million shares authorized; outstanding: — — 52 million shares at September 30, 2026, and 51 million at December 31, 2025 Preferred stock, $0.001 par value; 20 million shares authorized, no — — shares issued and outstanding Additional paid-in 536 452 capital Accumulated other comprehensive (loss) -95 15 income Retained earnings 3,714 3,602 Total stockholders’ 4,155 4,069 equity Total liabilities and stockholders’ $ 15,652 $ 15,564 equity
Nine Months Ended September 30, 2026 Operating activities: (In millions) 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 112 $ 632 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 117 151 Deferred income taxes -54 37 Share-based compensation 85 27 Impairment 93 — Other, net -21 -2 Changes in operating assets and liabilities: Receivables 174 -118 Prepaid expenses and other current 11 -25 assets Medical claims and benefits 101 -157 payable Amounts due government agencies -185 -467 Accounts payable, accrued liabilities 88 -195 and other Deferred revenue 16 -44 Income taxes 92 -76 Net cash provided by (used in) operating 629 -237 activities Investing activities: Purchases of investments -1,245 -607 Proceeds from sales and maturities of 1,020 1,017 investments Purchases of property, equipment, and -94 -102 capitalized software Net cash paid in business — -245 combinations Other, net -9 19 Net cash (used in) provided by investing -328 82 activities Financing activities: Proceeds from borrowings under credit — 1,100 facility and term loans Common stock purchases — -1,000 Repayment of credit facility and term — -360 loans Common stock withheld to settle employee -15 -37 tax obligations Other, net -16 35 Net cash used in financing -31 -262 activities Net increase (decrease) in cash, cash equivalents, and restricted 270 -417 cash and cash equivalents Cash, cash equivalents, and restricted cash and cash equivalents at 4,348 4,741 beginning of period Cash, cash equivalents, and restricted cash and cash equivalents at $ 4,618 $ 4,324 end of period
(Dollars in millions) The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Nine Months Ended September 30, 2026 Unaudited 2025 ────────────────────────────────────────────────────────────────────────────── Medical claims and benefits payable, $ 4,887 $ 4,640 beginning balance Components of medical care costs related to: Current year 28,781 29,476 Prior year -352 -124 Total medical care costs 28,429 29,352 Payments for medical care costs related to: Current year 24,692 25,425 Prior year 3,963 4,059 Total paid 28,655 29,484 Acquired balances, net of — 361 post-acquisition adjustments Change in non-risk and other 327 -25 payables Medical claims and benefits payable, $ 4,988 $ 4,844 ending balance Days in Claims Payable(1) 44 46
(1) The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements. -MORE- Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
(In millions, except per diluted share amounts) The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, impairments, and the impact of certain expenses and other items that management believes are not indicative of longer- term business trends and operations.
represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
__________________ (1) Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.
(2) This impairment charge results from the Company’s decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company’s strategic shift to focus exclusively on dual eligible members in Medicare.
(3) The nine months ended September 30, 2026 primarily includes non-recurring termination benefits, and the nine months ended September 30, 2025 includes non- recurring litigation costs. -MORE- Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
__________________ (1) Income tax effect calculated at the statutory tax rate of approximately 25.5%.
(2) Computations assume approximately 51.4 million diluted weighted average shares outstanding. -END-
Full text with the tables
News Release
Investor Contact: Jeffrey Geyer, [email protected] ,
305-317-3012
Media Contact: Caroline Zubieta, [email protected] ,
562-542-1845
Molina Healthcare Reports Third Quarter 2026 Financial Results
Reaffirms Full Year 2026 Earnings Guidance
Long Beach, Calif., October 21, 2026
– Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third
quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per
diluted share of $0.89. Financial results are summarized below:
Thr… Nine
mon… mon…
end… end…
Sep… Sep…
30, 30,
2026 20… 2026 20…
(…
m…
e…
p…
r…
P… $10… $1… $30… $3…
R…
T… $11… $1… $32… $3…
R…
G…
N… $38 $79 $112 $6…
I…
E…
– $0.… $1… $2.… $1…
D…
M…
C… 92… % 92.6 % 92… % 90.8 %
R…
(…
G… 6.4 % 6.4 % 6.8 % 6.5 %
R…
P… 0.5 % 0.8 % 0.5 % 2.4 %
M…
A…
N… $46 $97 $243 $7…
I…
E…
– $0.… $1… $4.… $1…
D…
G… 6.3 % 6.3 % 6.6 % 6.4 %
R…
P… 0.6 % 1.0 % 1.1 % 2.7 %
M…
S…
t…
R…
of
U…
N…
F…
M…
at
t…
e…
of
t…
r…
Quarter Highlights
• As of September 30, 2026, the Company served approximately 4.9 million
members.
• Premium revenue was approximately $10.5 billion for the third quarter of 2026.
• Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income
per diluted share was $0.89.
• The Company reaffirmed its full year 2026 guidance of expected premium revenue
of approximately $42 billion and adjusted earnings of at least $5.25 per diluted
share.
“We are pleased with our third quarter results in this challenging environment
and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief
Executive Officer. “With the apparent plateauing of medical cost trend, which
remains at elevated levels, and the strength of recent rate updates for 2027, we
believe we are likely observing the beginning of the turn in Medicaid margins.”
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 2
October 21, 2026
Premium Revenue
Premium revenue was approximately $10.5 billion for the third quarter of 2026, a
decrease of 4% year over year. The lower premium revenue reflects the impact of
lower membership in Medicaid and Marketplace, partially offset by rate updates.
Net Income
GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per
diluted share, a decrease of 52% year over year. Adjusted net income for the
third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of
53% year over year. The decrease is attributed mainly to a higher consolidated
MCR.
Medical Care Ratio (MCR)
• The consolidated MCR for the third quarter of 2026 was 92.9%.
• The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the
Company’s expectations, reflecting rate updates and stable medical cost trend.
• The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the
Company’s expectations, reflecting stable medical cost trend.
• The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with
normal seasonality and the Company’s expectations.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4%
and 6.3%, respectively, reflecting continued operating discipline.
Balance Sheet
Cash and investments at the parent company were approximately $608 million as of
September 30, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at September 30, 2026, was 44, consistent with June 30,
2026.
Cash Flow
Operating cash flow for the nine months ended September 30, 2026, was $629
million, compared to an outflow of $237 million for the nine months ended
September 30, 2025. The increase compared to the prior year was driven mainly by
lower government receivable and payable settlements in 2026.
2026 Guidance
Premium revenue guidance for the full year is unchanged at approximately $42
billion.
The Company expects its full year 2026 GAAP earnings to be at least $2.38 per
diluted share and reaffirmed its full year 2026 adjusted earnings of at least
$5.25 per diluted share. Guidance metrics across all segments are also
reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due
to the implementation of the new Florida Medicaid contract in the fourth quarter
of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD
product, which the Company previously announced it will exit for 2027.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 3
October 21, 2026
Conference Call
Management will host a conference call and webcast to discuss Molina
Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m.
Eastern Time on Thursday, October 22, 2026. The number to call for the
interactive teleconference is (877) 883-0383 and the confirmation number is
6534841. A telephonic replay of the conference call will be available through
Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation
number 4361465 . A live audio broadcast of this conference call will be
available on Molina Healthcare’s investor relations website,
investors.molinahealthcare.com . A 30-day online replay will be available
approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare
services under the Medicaid and Medicare programs and through the state
insurance marketplaces. For more information about Molina Healthcare, please
visit molinahealthcare.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain
forward-looking statements. The Company intends such forward-looking statements
to be covered under the safe harbor provisions for forward-looking statements
contained in Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements provide current
expectations of future events based on certain assumptions, and all statements
other than statements of historical fact contained in this earnings release and
the Company’s accompanying oral remarks may be forward-looking statements. In
some cases, you can identify forward-looking statements by words such as
“guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,”
“estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,”
“will,” “would,” “could,” “can,” “may,” or the negative of these terms or other
similar expressions. Forward-looking statements contained in this earnings
release include, but are not limited to, statements regarding the Company’s 2026
guidance and long-term performance outlook, trends with respect to rates, pretax
margins, utilization, and medical costs, including the timing thereof and the
anticipated impact on the Company’s business, and our management’s plans and
objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks
and uncertainties. These risks and uncertainties are discussed under the
headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s
Annual Report on Form 10‑K for the year ended December 31, 2025, which is on
file with the U.S. Securities and Exchange Commission (the “SEC”), and in the
Company’s other filings with the SEC, including its Quarterly Reports on Form
10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC
and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be
filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s
website or on the SEC’s website at sec.gov . Given these risks and
uncertainties, the Company can give no assurances that its forward-looking
statements will prove to be accurate, or that any other results or developments
projected or contemplated by its forward-looking statements will in fact occur,
and the Company cautions investors not to place undue reliance on these
statements. All forward-looking statements in this release represent the
Company’s judgment as of October 21, 2026, and, except as otherwise required by
law, the Company disclaims any obligation to update any forward-looking
statement to conform the statement to actual results or changes in its
expectations.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 4
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three
Months
Ended
Septem…
30,
2026 Nine
(In Months
millio… Ended
except Septem…
per-sh… 30,
Reven… amount… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Premi… $ 10,457 $ 10,841 $ 30,873 $ 32,337
reven…
Premi…
tax 500 506 1,509 1,325
reven…
Inves… 102 108 301 322
income
Other 23 22 69 67
reven…
Total 11,082 11,477 32,752 34,051
reven…
Opera…
expen…
Medic…
care 9,719 10,044 28,429 29,352
costs
Gener…
and 710 729 2,213 2,214
admin…
expen…
Premi…
tax 500 506 1,509 1,325
expen…
Depre…
and 38 45 117 151
amort…
Impai… — — 93 —
Other 9 16 57 66
Total
opera… 10,976 11,340 32,418 33,108
expen…
Opera… 106 137 334 943
income
Inter… 53 49 161 140
expen…
Income
before
income 53 88 173 803
tax
expen…
Income
tax 15 9 61 171
expen…
Net $ 38 $ 79 $ 112 $ 632
income
Net
income
per $ 0.73 $ 1.51 $ 2.19 $ 11.79
share
–
Dilut…
Dilut…
weigh…
avera… 51.5 52.5 51.3 53.6
shares
outst…
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 5
October 21, 2026
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
September 30,
2026
Unaudited
(Dollars in
millions,
ASSETS except per-share December 31,
Current assets: amounts) 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 4,479 $ 4,248
equivalents
Investments 4,100 4,008
Receivables 3,359 3,533
Prepaid expenses and
other current 576 655
assets
Total current assets 12,514 12,444
Property, equipment,
and capitalized 324 301
software, net
Goodwill and
intangible assets, 2,073 2,195
net
Restricted 345 299
investments
Deferred income 267 178
taxes, net
Other assets 129 147
Total assets $ 15,652 $ 15,564
LIABILITIES AND
STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and $ 4,988 $ 4,887
benefits payable
Amounts due 1,141 1,326
government agencies
Accounts payable,
accrued liabilities 1,183 1,093
and other
Deferred revenue 82 66
Total current 7,394 7,372
liabilities
Long-term debt 3,771 3,766
Finance lease 179 184
liabilities
Other long-term 153 173
liabilities
Total liabilities 11,497 11,495
Stockholders’
equity:
Common stock, $0.001
par value, 150
million shares
authorized;
outstanding: — —
52 million shares at
September 30, 2026,
and 51 million at
December 31, 2025
Preferred stock,
$0.001 par value; 20
million shares
authorized, no — —
shares
issued and
outstanding
Additional paid-in 536 452
capital
Accumulated other
comprehensive (loss) -95 15
income
Retained earnings 3,714 3,602
Total stockholders’ 4,155 4,069
equity
Total liabilities
and stockholders’ $ 15,652 $ 15,564
equity
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 6
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,
2026
Operating activities: (In millions) 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 112 $ 632
Adjustments to reconcile net
income to
net cash provided by (used in)
operating
activities:
Depreciation and amortization 117 151
Deferred income taxes -54 37
Share-based compensation 85 27
Impairment 93 —
Other, net -21 -2
Changes in operating assets and
liabilities:
Receivables 174 -118
Prepaid expenses and other
current 11 -25
assets
Medical claims and benefits 101 -157
payable
Amounts due government agencies -185 -467
Accounts payable, accrued
liabilities 88 -195
and other
Deferred revenue 16 -44
Income taxes 92 -76
Net cash provided by (used in)
operating 629 -237
activities
Investing activities:
Purchases of investments -1,245 -607
Proceeds from sales and
maturities of 1,020 1,017
investments
Purchases of property,
equipment, and -94 -102
capitalized software
Net cash paid in business — -245
combinations
Other, net -9 19
Net cash (used in) provided by
investing -328 82
activities
Financing activities:
Proceeds from borrowings under
credit — 1,100
facility and term loans
Common stock purchases — -1,000
Repayment of credit facility
and term — -360
loans
Common stock withheld to settle
employee -15 -37
tax obligations
Other, net -16 35
Net cash used in financing -31 -262
activities
Net increase (decrease) in
cash, cash
equivalents, and restricted 270 -417
cash and
cash equivalents
Cash, cash equivalents, and
restricted
cash and cash equivalents at 4,348 4,741
beginning
of period
Cash, cash equivalents, and
restricted
cash and cash equivalents at $ 4,618 $ 4,324
end of
period
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 7
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)
September December September
30, 31, 30,
2026 2025 2025
Ending
Member…
by
Segmen…
Medica… 4,372,0… 4,568,0… 4,639,0…
Medica… 222,000 262,000 266,000
Market… 267,000 655,000 713,000
Other 1,000 6,000 10,000
Total 4,862,0… 5,491,0… 5,628,0…
Th…
Mo…
En…
Se…
30,
Pr… Me… Pr… Me…
Re… 2… Ma… MC… Re… 2… Ma… MC…
──────────────────────────────────────────────────────────────────────────────
M… $ 8… $ 5… 9… % $ 8… $ 6… 9… %
M… 1… 1… 9… 1… 1… 9…
M… 6… 48 9… 1… 53 9…
O… — — NM 19 2 NM
C… $ 1… $ 7… 9… % $ 1… $ 7… 9… %
N…
M…
E…
S…
3…
P… M… P… M…
R… 20… M… M… R… 20… M… M…
──────────────────────────────────────────────────────────────────────────────
M… $ 24… $ 1,… 92… % $ 24… $ 2,… 91… %
M… 4,… 413 91… 4,… 436 90…
M… 1,… 233 88… 3,… 411 87…
O… 6 5 NM 76 11 NM
C… $ 30… $ 2,… 92… % $ 32… $ 2,… 90… %
(…
M…
r…
m…
c…
as
a
p…
of
p…
r…
(…
T…
O…
M…
a…
n…
m…
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 8
October 21, 2026
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for
moderately adverse conditions based on historical experience and other factors
including, but not limited to, variations in claims payment patterns, changes in
utilization and cost trends, known outbreaks of disease, and large claims. The
Company’s reserving methodology is consistently applied across all periods
presented. The amounts displayed for “Components of medical care costs related
to: Prior year” represent the amounts by which the original estimates of claims
and benefits payable at the beginning of the year were more than the actual
liabilities based on information (principally the payment of claims) developed
since those liabilities were first reported. The following table presents the
components of the change in medical claims and benefits payable for the periods
indicated:
Nine Months Ended
September 30,
2026
Unaudited 2025
──────────────────────────────────────────────────────────────────────────────
Medical claims and benefits
payable, $ 4,887 $ 4,640
beginning balance
Components of medical care
costs related
to:
Current year 28,781 29,476
Prior year -352 -124
Total medical care costs 28,429 29,352
Payments for medical care costs
related
to:
Current year 24,692 25,425
Prior year 3,963 4,059
Total paid 28,655 29,484
Acquired balances, net of — 361
post-acquisition adjustments
Change in non-risk and other 327 -25
payables
Medical claims and benefits
payable, $ 4,988 $ 4,844
ending balance
Days in Claims Payable(1) 44 46
__________________
(1) The Company calculates Days in Claims Payable using claims incurred but not
paid, or IBNP, and other fee-for-service payables included in medical claims and
benefits payable, and quarterly fee-for-service related costs included in
medical care costs within the Company’s consolidated financial statements.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 9
October 21, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting
principles) financial measures are useful supplemental measures to investors in
comparing the Company’s performance to the performance of other public companies
in the health care industry. The non-GAAP financial measures are also used
internally to enable management to assess the Company’s performance consistently
over time. These non-GAAP financial measures, presented below, should be
considered as supplements to, and not as substitutes for or superior to, GAAP
measures.
Adjustments
represent additions and deductions to GAAP net income as indicated in the table
below, which include the non-cash impact of amortization of acquired intangible
assets, acquisition-related expenses, impairments, and the impact of certain
expenses and other items that management believes are not indicative of longer-
term business trends and operations.
Adjusted G&A Ratio
represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income
represents GAAP net income recognizing the adjustments, net of tax. The Company
believes that adjusted net income is helpful to investors in assessing the
Company’s financial performance.
Adjusted net income per diluted share
represents adjusted net income divided by weighted average common shares
outstanding on a fully diluted basis.
Adjusted pre-tax margin
represents adjusted income before income tax expense, divided by total revenue.
… …
… …
… …
… … … … …
… … … … …
… … … … … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … $ … $ … $ … …
$ … $ … $ … $ … $ … $ … …
— — 4 … … … …
— — — — … — —
— — … … … 1 …
… … … … … … …
… … … … … … …
8 … … … … … …
$ … $ … $ … $ … $ … $ … …
__________________
(1) Reflects non-recurring costs associated with acquisitions, including various
transaction and certain integration costs.
(2) This impairment charge results from the Company’s decision to exit the
Medicare Advantage Prescription Drug product for 2027 as that product does not
align with the Company’s strategic shift to focus exclusively on dual eligible
members in Medicare.
(3) The nine months ended September 30, 2026 primarily includes non-recurring
termination benefits, and the nine months ended September 30, 2025 includes non-
recurring litigation costs.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 10
October 21, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2026 GUIDANCE
Per Diluted
Amount Share(2)
────────────────────────────────────────────────────────────────────────
GAAP Net income $ 122 $ 2.38
Adjustments:
Acquisition-related expenses 48 0.89
Amortization of intangible assets 36 0.70
Impairment 93 1.82
Other 21 0.44
Subtotal, adjustments 198 3.85
Income tax effect(1) -50 -0.98
Adjustments, net of tax 148 2.87
Adjusted net income $ 270 $ 5.25
__________________
(1) Income tax effect calculated at the statutory tax rate of approximately
25.5%.
(2) Computations assume approximately 51.4 million diluted weighted average
shares outstanding.
-END-